Trial reportJournal of cosmetic dermatology2025
Clinical Observation of a Novel Moisturizing Cream for Reducing Neurovascular Hyper-Reactivity in Sensitive Skin.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Observation of a Novel Moisturizing Cream for Reducing Neurovascular Hyper-Reactivity in Sensitive Skin.Journal of cosmetic dermatology · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSensitive skin is a syndrome characterized by unpleasant sensations in response to external stimuli. Its pathogenesis is linked to impaired skin barrier function, leading to neurovascular hyper-reactivity and inflammation. While topical functional skincare products are known to repair sensitive skin, there are limited reports on products specifically targeting the reduction of neurovascular hyper-reactivity.
objectiveTo evaluate the efficacy and safety of a novel cream in improving neurovascular hyper-reactivity and subjective symptoms in sensitive skin.
methodsThis randomized, double-blind, self-controlled trial included 35 participants. One side of the face was treated with experimental cream (Group A) and the other with control cream (Group B), applied twice daily for 28 days. Follow-up assessments were performed on Day 0, Day 7, Day 14, and Day 28, with 28-day post-trial safety monitoring. Evaluations included clinical evaluation by physician, participant self-assessment of symptoms, measurements of skin physiological parameters and current perception threshold (CPT), lactic acid stinging test (LAST), capsaicin pain test (CAT), product usage experience, and participant tolerance.
resultsThe experimental cream demonstrates good safety and user experience. Both the experimental and control creams effectively improve symptoms and signs of sensitive skin, increase SC hydration, and lower TWEL, LAST, and DLQI scores. Additionally, the experimental cream outperforms the control cream in improving pruritus, erythema, and TWEL. The experimental cream also has the unique advantage of reducing CAT scores and increasing CPT.
conclusionThe new cream has good safety and can effectively reduce neurovascular hyper-reactivity, alleviating symptoms in individuals with sensitive skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.